Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of CDC will - over the next 2 Weeks and hit - by . In that time frame, CDC's share price is expected to range between - and -.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No Data | |||||||||||||||||||
CDC shares rose +0.32% in Thursday, April 2, 2026's trading session, rising from a previous close of $71.12 to move at $71.35. The stock demonstrated notable intraday movement (see CDC's key stats for a full breakdown), fluctuating between $70.79 and $71.48, a +0.97% trading range. While recent weeks have seen some volatility, CDC has managed to secure a +1.32% gain over the past 2 weeks. The upward price movement was accompanied by increased trading volume, with approximately 15.88K shares changing hands, 6.31K more than the previous session. This amounted to $1.13M in total market activity.
Will CDC Continue Its Trend?
According to analyst ratings and projections for CDC, VictoryShares US EQ Income Enhanced Volatility Wtd ETF shares are anticipated to remain stable by -, potentially reaching - per share by January 1, 1970. Short-term technical indicators currently suggest a bearish sentiment for CDC. However, the stock has recorded 16 positive trading days within the past 30 sessions. Based on the CDC stock forecast, now is not the best time to buy CDC stock because its current trading price is - our predicted value, hinting at a possible . For deeper insights, view our sentiment analysis on CDC covering social and institutional perspectives.
CDC Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into CDC's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 51.93% to 54.67%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 55.22%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 55.07%, maintains a neutral outlook for the long term. Insights into CDC's shareholder base show how institutional investors are positioning themselves during these momentum shifts

